secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-05-12T20:10:14+00:00
Accession:  0001725160-26-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.
- DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.
- ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.
- Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/0001725160-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntl-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer